丙戊酸镁缓释片联合碳酸锂治疗躁狂发作的临床分析  

Magnesium valproate sustained-release tablets plus lithium in treatment of manic episodes of clinical

作　　者：穆小梅 魏长礼 张子明[1] 洪贵子 王秀梅[1] 

机构地区：[1]甘肃省天水市第三人民医院,741000

出　　处：《中国医学创新》2011年第4期13-15,共3页Medical Innovation of China

摘　　要：目的探讨丙戊酸镁缓释片联合碳酸锂与碳酸锂治疗躁狂发作的疗效与安全性。方法将52例符合中国精神障碍分类与诊断标准第3版(CCMD-3)躁狂发作诊断标准的患者随机分为研究组(26例)和对照组(26例),研究组应用丙戊酸镁缓释片、碳酸锂以及非典型抗精神病药物利培酮。对照组应用碳酸锂联合与利培酮治疗,疗程6周。用躁狂评定量表(BRMS)与副反应量表(TESS)分别评定疗效及不良反应观察6周。结果研究组和对照组6周治疗后与治疗前的BRMS评分差异均具有统计学意义(P<0.01),研究组和对照组6周末的BRMS评分及显效率均具有统计学意义(P<0.05),2组的副作用相似,组间主要副作用发生率的差异无统计学意义(P>0.05)。结论丙戊酸镁缓释片联合碳酸锂控制躁狂发作的疗效优于碳酸锂治疗,安全性良好。Objectve Magnesium valproate tablets of lithium carbonate and lithium carbonate in treatment of joint manic episode of the efficacy and safety. Methods 52 patients met the Chinese Classification and Diagnostic Criteria of Mental Disorders Version 3 （CCMD -3 ） diagnostic criteria for manic episode were randomly divided into study group （26 cases） and control group （26 cases）, Application of magnesium valproate group sustained release tablets, lithium and atypical antipsychotic risperidone. Control group were combined lithium and risperidone, treatment 6 w. Mania rating scale used （BRMS） and the side effects scale （TESS） assessed the efficacy and adverse reactions were observed for 6 weeks. Results The study group and control group after 6 weeks of treatment before treatment BRMS score differences were statistically significant（ P 〈 0. 01 ） ,study group and control group,6 weeks,and markedly effective rate of BRMS scores were statistically significant （P 〈 0. 05 ）. 2 groups had similar adverse events, groups, the incidence of major side effects were no significant differences （P 〉 0. 05 ）. Conclusion The magnesium valproate combined lithium carbonate controlled release tablets manic episode is better than lithium in treatment efficacy, security is good.

关 键 词：丙戊酸镁缓释片 碳酸锂 躁狂发作 

分 类 号：R749.4[医药卫生—神经病学与精神病学]